AMRX Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio44.00Forward 6.30
EPS (TTM)$0.37384.6% YoY
Profit margin4.0%HEALTHCARE
Market cap$5.19BMid cap
Wall Street coverage
$17.25median target· current $6.75 (+155.6%)5 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- 6.30
- PEG ratio
- —
- P/B
- 105.45
- P/S (TTM)
- 1.71
- EV/EBITDA
- 12.28
Profitability & growth
- ROE (TTM)
- -881.0%
- Operating margin
- 19.6%
- Revenue growth YoY
- 3.9%
- Dividend yield
- —
- Beta
- 1.32
Last earnings
May 7, 2026 · Estimate $0.19 · Reported $0.27
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Company profileAmneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company is headquartered in Bridgewater, New Jersey.
Classification
- Sector
- Healthcare
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 400 CROSSING BOULEVARD, BRIDGEWATER, NJ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$5.19B
Shares outstanding$319.0M
52W high$16.61
52W low$7.67
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent